Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma.
April K S SalamaManisha PaltaChristel N RushingM Angelica SelimKristen N LinneyBrian G CzitoDavid S YooBrent A HanksGeorgia M BeasleyPaul J MoscaChelsae DumbauldKatelyn N SteadmanJohn S YiKent J WeinholdDouglas S TylerWalter T LeeDavid M BrizelPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Overall, concurrent administration of ipilimumab and radiation was feasible, and resulted in a high response rate, converting some patients with unresectable disease into surgical candidates. Additional studies to investigate the combination of radiation and checkpoint inhibitor therapy are warranted.